Buy or sell: Stock recommendation by brokers for November 25, 2025

R Amin03 mins mins

<h2>Buy</h2> <p> or sell: Stock recommendation by brokers for November 25, 2025″ title=”Representative image” decoding=”async” fetchpriority=”high”/></p></div> </div> </div> </section> </div></div> </div> <p>Emkay Global has downgraded ACC to sell due to weak margin trends and slower capex execution with the target price cut sharply to Rs 1,600 from Rs 2,280.</p> <p>Analysts said that ACC’s valuation revised to 7x EV/EBITDA (economic value/earnings before interest, taxes, depreciation and amortisation from 9x given deteriorating fundamentals.<!-- --> They have cut ACC’s FY27 expected EBITDA cut by about 12%, reflecting margin pressure and a higher traded mix.</p> <p>Analysts said that higher inter-group trading is impacting margins and operational independence.</p> <p>A rising share of traded goods limits pricing power and premiumization ability.</p> <p>They also pointed out that ACC’s working capital (WC) worsened significantly to 57 days from earlier negative WC levels.</p> <p>Also, cash reserves dropped to a multi-year low (Rs 880 crore) due to higher working capital consumption.</p> <p><!-- -->They also pointed out that ACC’s capacity expansion is expected at only ~7% compounded annual rate over FY25-FY28, which is seen as below expectations.</p> <p>They also said they would prefer Ambuja Cements over ACC due to better profitability, scale, and synergy benefits within the group.<span class=CLSA maintained its outperform rating on Hindustan Aeronautics with the target price at Rs 5,436.

Analysts said that Tejas Mk1, one of the aircraft manufactured by HAL, went down at the Dubai Air Show last week.

Experts highlight three possible causes: sudden loss of thrust from GE engine, biological effects of aerodynamic stall induced during a negative-G manoeuvre or human error.UBS has initiated its coverage of Shaily Engineering with a buy rating and a target price of Rs 4,000.

Analysts feel the company has high potential, high growth and high optionality with multiple growth levers and the potential for positive surprises ahead.

They feel the company is on strong footing for generic semaglutide launch.

They also expect the company’s consumer and industrial businesses to grow steadily with consumer electronics an optionality.Jefferies has a buy on Shyam Metalics with the target price at Rs 1,050.

Analysts said the company has a growth mindset and offers one of the best growth potentials in India’s metals space, underpinned by capacity expansions and healthy balance sheet.

They expect the company is poised to become one of India’s top-3 stainless steel manufacturers while also expanding cold rolled steel and intermediates volumes.Nomura has a buy on IKS Health with the target price at Rs 2,000.

Analysts feel the company is an attractive play on the US healthcare provider space with the US healthcare outsourcing market likely to record a 12% compounded annual growth rate (CAGR) over CY23-CY28.

The company offers a comprehensive and integrated platform stack with next-gen tech capabilities.Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India.

Always consult with a qualified investment advisor or financial planner before making any investment decisions.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News